LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical firm traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), at this time introduced that will probably be conducting one-on-one digital conferences with institutional traders as a part of the Lytham Partners Fall 2022 Investor Conference. The occasion is happening nearly on September 28 – 29, 2022.
Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O’Brien, JD/MBA, Vice President and Executive Officer, might be obtainable for one-on-one conferences at this convention and traders could request a one-on-one assembly by contacting Joe Diaz of Lytham Partners by telephone at (602) 889-9660, by e mail at [email protected] or by registering at https://www.lythampartners.com/fall2022invreg/.
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical firm creating a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative ailments. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with a number of mechanisms of motion and powerful security profiles, MediciNova has 11 applications in scientific growth. MediciNova’s lead asset, MN-166 (ibudilast), is presently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive a number of sclerosis (MS). MN-166 (ibudilast) can be being evaluated in Phase 2 trials in glioblastoma and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver illness (NAFLD) is ongoing. MediciNova has a robust observe file of securing investigator-sponsored scientific trials funded by way of authorities grants.
Statements in this press launch that aren’t historic in nature represent forward-looking statements inside the which means of the secure harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements embody, with out limitation, statements concerning the future growth and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements could also be preceded by, adopted by, or in any other case embody the phrases “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “can,” “could,” “may,” “will,” “would,” “considering,” “planning” or related expressions. These forward-looking statements contain various dangers and uncertainties which will trigger precise outcomes or occasions to differ materially from these expressed or implied by such forward-looking statements. Factors which will trigger precise outcomes or occasions to differ materially from these expressed or implied by these forward-looking statements embody, however usually are not restricted to, dangers of acquiring future accomplice or grant funding for growth of MN-166, MN-001, MN-221, and MN-029 and dangers of elevating adequate capital when wanted to fund MediciNova’s operations and contribution to scientific growth, dangers and uncertainties inherent in scientific trials, together with the potential value, anticipated timing and dangers related to scientific trials designed to meet FDA steerage and the viability of additional growth contemplating these elements, product growth and commercialization dangers, the uncertainty of whether or not the outcomes of scientific trials might be predictive of outcomes in later phases of product growth, the danger of delays or failure to get hold of or keep regulatory approval, dangers related to the reliance on third events to sponsor and fund scientific trials, dangers concerning mental property rights in product candidates and the skill to defend and implement such mental property rights, the danger of failure of the third events upon whom MediciNova depends to conduct its scientific trials and manufacture its product candidates to carry out as anticipated, the danger of elevated value and delays due to delays in the graduation, enrollment, completion or evaluation of scientific trials or vital points concerning the adequacy of scientific trial designs or the execution of scientific trials, and the timing of anticipated filings with the regulatory authorities, MediciNova’s collaborations with third events, the availability of funds to full product growth plans and MediciNova’s skill to get hold of third get together funding for applications and lift adequate capital when wanted, and the different dangers and uncertainties described in MediciNova’s filings with the Securities and Exchange Commission, together with its annual report on Form 10-Okay for the yr ended December 31, 2021 and its subsequent periodic studies on Form 10-Q and present studies on Form 8-Okay. Undue reliance shouldn’t be positioned on these forward-looking statements, which communicate solely as of the date hereof. MediciNova disclaims any intent or obligation to revise or replace these forward-looking statements.
INVESTOR CONTACT:
Geoff O’Brien
Vice President
MediciNova, Inc.
[email protected]
